Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

Published on Jan 22, 2020in Scientific Reports4.38
· DOI :10.1038/S41598-020-57935-6
Mitsuhiro Kawakubo1
Estimated H-index: 1
(Nagoya University),
Miyako Tanaka21
Estimated H-index: 21
(Nagoya University)
+ 17 AuthorsMichiko Itoh16
Estimated H-index: 16
(Tokyo Medical and Dental University)
Nonalcoholic steatohepatitis (NASH) is a hepatic phenotype of the metabolic syndrome, and increases the risk of cirrhosis and hepatocellular carcinoma (HCC). Although increasing evidence points to the therapeutic implications of certain types of anti-diabetic agents in NASH, it remains to be elucidated whether their effects on NASH are independent of their effects on diabetes. Genetically obese melanocortin 4 receptor–deficient (MC4R-KO) mice fed Western diet are a murine model that sequentially develops hepatic steatosis, NASH, and HCC in the presence of obesity and insulin resistance. In this study, we investigated the effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor anagliptin on NASH and HCC development in MC4R-KO mice. Anagliptin treatment effectively prevented inflammation, fibrosis, and carcinogenesis in the liver of MC4R-KO mice. Interestingly, anagliptin only marginally affected body weight, systemic glucose and lipid metabolism, and hepatic steatosis. Histological data and gene expression analysis suggest that anagliptin treatment targets macrophage activation in the liver during the progression from simple steatosis to NASH. As a molecular mechanism underlying anagliptin action, we showed that glucagon-like peptide-1 suppressed proinflammatory and profibrotic phenotypes of macrophages in vitro. This study highlights the glucose metabolism–independent effects of anagliptin on NASH and HCC development.
📖 Papers frequently viewed together
20123.24PLOS ONE
19 Authors (Yuki Kita, ..., Shuichi Kaneko)
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the degradation of glucagon-like peptide-1 (GLP-1) and improve glycemic control. The GLP-1 insulinotropic effect involves a pathway through vagus nerve GLP-1 receptors in the gut, in addition to a direct effect on the pancreas. Therefore, this study verified whether DPP-4 inhibition in the gut contributed to the improvement of glycemic control. Anagliptin, a DPP-4 inhibitor, was administered orally or subcutaneously (with or without pass...
#1Geoff Farrell (ANU: Australian National University)H-Index: 5
Last. Detlef Schuppan (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 117
view all 7 authors...
: Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental factors and genetic determinants that cannot be completely replicated in animals. Notwithstanding, preclinical models are needed to understand NASH pathophysiology and test mechanism-based therapies. Among several mouse models of NASH, some exhibit the key pathophysiologic as well as histopathologic criteria for human NASH, whereas others may be useful to address specific questions. Models based on overn...
#1Clémence Hollande (UPMC: Pierre-and-Marie-Curie University)H-Index: 4
#2Jeremy Boussier (Pasteur Institute)H-Index: 10
Last. Matthew L. Albert (Genentech)H-Index: 67
view all 16 authors...
Post-translational modification of chemokines mediated by the dipeptidyl peptidase DPP4 (CD26) has been shown to negatively regulate lymphocyte trafficking, and its inhibition enhances T cell migration and tumor immunity by preserving functional chemokine CXCL10. By extending those initial findings to pre-clinical models of hepatocellular carcinoma and breast cancer, we discovered a distinct mechanism by which inhibition of DPP4 improves anti-tumor responses. Administration of the DPP4 inhibitor...
#1Elodie M. Varin (Lunenfeld-Tanenbaum Research Institute)H-Index: 12
#2Erin E. Mulvihill (Lunenfeld-Tanenbaum Research Institute)H-Index: 23
Last. Daniel J. Drucker (U of T: University of Toronto)H-Index: 143
view all 13 authors...
Summary Dipeptidyl peptidase-4 (DPP-4) controls glucose homeostasis through enzymatic termination of incretin action. We report that plasma DPP-4 activity correlates with body weight and fat mass, but not glucose control, in mice. Genetic disruption of adipocyte Dpp4 expression reduced plasma DPP-4 activity in older mice but did not perturb incretin levels or glucose homeostasis. Knockdown of hepatocyte Dpp4 completely abrogated the obesity-associated increase in plasma DPP-4 activity, reduced l...
#1Ilaria Dicembrini (UniFI: University of Florence)H-Index: 27
#2Matteo Monami (UniFI: University of Florence)H-Index: 59
Last. Edoardo Mannucci (UniFI: University of Florence)H-Index: 98
view all 3 authors...
Abstract Dypeptidylpeptidase-4 (DPP-4) inhibitors are a therapeutic option for improving glucose control in patients with type 2 diabetes. They can be prescribed at different stages of the natural history of the disease because of their low risk for hypoglycemia and associated weight gain. For all new drugs for diabetes, the US Food and Drug Administration requires the demonstration of the cardiovascular (CV) safety profile through pooled analyses of phase 3 studies or specifically designed tria...
#1Sohji Nishina (Kawasaki Medical School)H-Index: 12
#2Akira Yamauchi (Kawasaki Medical School)H-Index: 52
Last. Keisuke Hino (Kawasaki Medical School)H-Index: 34
view all 11 authors...
Background & Aims CD26, a multifunctional transmembrane glycoprotein, is expressed in various cancers and functions as dipeptidyl peptidase 4 (DPP4). We investigated whether CD26 expression is associated with hepatocellular carcinoma (HCC) progression and whether DPP4 inhibitors exert antitumor effects against HCC. Methods CD26 expression was examined in 41 surgically resected HCC specimens. The effects of DPP4 inhibitors on HCC were examined by using HCC cell lines (Huh-7 and Li-7), xenograft t...
Aim: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is known to be associated with type 2 diabetes mellitus (T2DM) in high rate. The improvement in hepatic function due to sodium-glucose co-transporter 2 (SGLT2) inhibitors has been reported in T2DM patients with and without NAFLD. However, only a few studies have attempted to evaluate the role of SGLT2 inhibitors in T2DM patients with biopsy-proven NASH, and no detailed prospective studies including the ...
#3Vincent Wai-Sun Wong (CUHK: The Chinese University of Hong Kong)H-Index: 1
Background & Aims Little is known about the natural course of nonalcoholic fatty liver disease (NAFLD) with advanced fibrosis. We describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in patients with advanced NAFLD. Methods We conducted a multi-national study of 458 patients with biopsy-confirmed NAFLD with bridging fibrosis (F3, n = 159) or compensated cirrhosis (222 patients with Child-Turcotte-Pugh scores of A5 and 77 patients with ...
#5Ibuki Shirakawa (Tokyo Medical and Dental University)H-Index: 8
Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). However, it is still unclear how FXR agonists protect against NASH and which cell type is the main target of FXR agonists. In this study, we examined the effects of OCA on the development of NASH using melanocortin 4 receptor-deficient (MC4R-KO) mice that progressively developed hepatic steatosis and NASH on Western diet...
#7Soona Shin (Cincinnati Children's Hospital Medical Center)H-Index: 18
: Recent publications show that classic hepatoblastoma (HBL) is the result of failure of hepatic stem cells to differentiate into hepatocytes, while hepatocellular carcinoma (HCC) is caused by the dedifferentiation of hepatocytes into cancer stem cells. However, the mechanisms of aggressive HBL and the mechanisms that cause dedifferentiation of hepatocytes into cancer stem cells are unknown. We found that, similar to HCC but opposite to classic HBL, aggressive HBL is the result of dedifferentiat...
Cited By16
#1C Wendy Spearman (UCT: University of Cape Town)H-Index: 12
#2Mary Afihene (KNUST: Kwame Nkrumah University of Science and Technology)H-Index: 10
Last. Ojo Os (OAU: Obafemi Awolowo University)H-Index: 9
view all 13 authors...
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally and is estimated to affect approximately 25% of the world's population. Data about the prevalence and incidence of NAFLD in Africa are scarce, but the prevalence is estimated to be 13·5% for the general population. This is likely to be an underestimate considering the increasing burden of non-communicable diseases, particularly the rising prevalence of obesity and type 2 diabetes, driven by the overl...
#1Sahar H Elhini (Minia University)H-Index: 1
#2Amal Kmal Hussien (Minia University)
Last. Haitham Saeed (Beni-Suef University)H-Index: 10
view all 5 authors...
Type 2 diabetes mellitus (T2DM) is a chronic and progressive disease that requires long-term management. Thus, dipeptidyl peptidase-4 inhibitors (DPP-4) need more investigations about their efficacy and safety profile as there is still no evidence of whether DPP-4 inhibitors can be used as a first line option for T2DM drug-naive patients. In this randomized case-controlled study, 60 drug-naive T2DM subjects were randomized into three groups, each group comprising 20 subjects. Group 1 was given s...
#1Danny Orabi (Cleveland Clinic Lerner Research Institute)H-Index: 1
#2Nathan A. Berger (Case Western Reserve University)H-Index: 59
Last. J. Mark BrownH-Index: 20
view all 3 authors...
Nonalcoholic fatty liver disease (NAFLD) is on the rise and becoming a major contributor to the development of hepatocellular carcinoma (HCC). Reasons for this include the rise in obesity and metabolic syndrome in contrast to the marked advances in prevention and treatment strategies of viral HCC. These shifts are expected to rapidly propel this trend even further in the coming decades, with NAFLD on course to become the leading etiology of end-stage liver disease and HCC. No Food and Drug Admin...
#1Daniel Ferguson (WashU: Washington University in St. Louis)H-Index: 6
#2Brian N. Finck (WashU: Washington University in St. Louis)H-Index: 41
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease in the world, yet there are still no approved pharmacological therapies to prevent or treat this condition. NAFLD encompasses a spectrum of severity, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Although NASH is linked to an increased risk of hepatocellular carcinoma and cirrhosis and has now become the leading cause of liver failure-related transplantation, the majority of patient...
#1Takeshi Nitta (UTokyo: University of Tokyo)H-Index: 28
#2Ayami Ota (UTokyo: University of Tokyo)H-Index: 1
Last. Hiroshi Takayanagi (UTokyo: University of Tokyo)H-Index: 85
view all 5 authors...
Fibroblasts have recently attracted attention as a key stromal component that controls the immune responses in lymphoid tissues. The thymus has a unique microenvironment comprised of a variety of stromal cells, including fibroblasts and thymic epithelial cells (TECs), the latter of which is known to be important for T cell development because of their ability to express self-antigens. Thymic fibroblasts contribute to thymus organogenesis during embryogenesis and form the capsule and medullary re...
#1Naoki Yoshioka (Nagoya University)H-Index: 7
#2Miyako Tanaka (Nagoya University)H-Index: 21
Last. Takayoshi Suganami (Nagoya University)H-Index: 55
view all 15 authors...
Abstract Background Diabetes and obesity contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). However, how diabetes and obesity accelerate liver tumorigenesis remains to be fully understood. Moreover, to verify the therapeutic potential of anti-diabetic drugs, there exists a strong need for appropriate animal models that recapitulate human pathophysiology of NASH and HCC. Methods We established a novel murine model of NASH-associated liver tum...
#2Pratik Adhikary (UMKC: University of Missouri–Kansas City)H-Index: 2
Liver fibrosis is the excessive accumulation of extracellular matrix due to chronic injuries, such as viral infection, alcohol abuse, high-fat diet, and toxins. Liver fibrosis is reversible before it progresses to cirrhosis and hepatocellular carcinoma. Type 2 diabetes significantly increases the risk of developing various complications including liver diseases. Abundant evidence suggests that type 2 diabetes and liver diseases are bidirectionally associated. Patients with type 2 diabetes experi...
#1Anna Veelen (UM: Maastricht University)H-Index: 1
#2Edmundo Erazo-Tapia (Maastricht University Medical Centre)H-Index: 1
Last. Patrick Schrauwen (UM: Maastricht University)H-Index: 96
view all 4 authors...
Abstract Background Type 2 diabetes is a syndrome defined by hyperglycaemia that is the result of various degrees of pancreatic β-cell failure and reduced insulin sensitivity. Despite the fact that diabetes can be caused by multiple metabolic dysfunctions, the majority of patients are defined as having either type 1 or type 2 diabetes. Recently, Ahlqvist and colleagues proposed a new way to classify patients with adult-onset diabetes, taking the heterogenous metabolic phenotype of the disease in...
#1Chuo Li (Guangzhou Medical University)H-Index: 2
#2Yusheng Zhang (JNU: Jinan University)H-Index: 12
Last. Yuzhen Mai (Guangzhou Medical University)H-Index: 2
view all 4 authors...
Background and purpose Cerebral ischemia-reperfusion injury is commonly induced during the treatment of ischemic stroke and is reported to be related to the blood-brain barrier destruction and brain vascular endothelial cell dysfunction. Anagliptin is a novel antidiabetic agent recently reported to protect neurons from oxidative stress. In the present study, we aim to investigate the protective property of anagliptin against oxygen-glucose deprivation and reperfusion (OGD/R)-induced injury on en...
#1Paola Dongiovanni (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 58
#2Erika Paolini (University of Milan)H-Index: 3
Last. Massimiliano Ruscica (University of Milan)H-Index: 37
view all 5 authors...
BACKGROUND A consensus of experts has proposed to replace the term nonalcoholic fatty liver disease (NAFLD), whose global prevalence is 25%, with metabolic dysfunction-associated fatty liver disease (MAFLD), to describe more appropriately the liver disease related to metabolic dysfunction. MAFLD is closely intertwined with type 2 diabetes, obesity, dyslipidemia, all linked to a rise in the risk of cardiovascular disease (CVDs). Since controversy still stands on whether or not NAFLD/MAFLD raises ...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.